JP2017519491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519491A5 JP2017519491A5 JP2016565693A JP2016565693A JP2017519491A5 JP 2017519491 A5 JP2017519491 A5 JP 2017519491A5 JP 2016565693 A JP2016565693 A JP 2016565693A JP 2016565693 A JP2016565693 A JP 2016565693A JP 2017519491 A5 JP2017519491 A5 JP 2017519491A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- terminal
- epitope
- mhc
- multimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 288
- 229920001184 polypeptide Polymers 0.000 claims description 286
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 286
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 65
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 65
- 210000004899 c-terminal region Anatomy 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 24
- 230000002519 immonomodulatory effect Effects 0.000 claims description 22
- 230000004957 immunoregulator effect Effects 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 14
- 238000003259 recombinant expression Methods 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 10
- 102000043129 MHC class I family Human genes 0.000 claims description 7
- 108091054437 MHC class I family Proteins 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 5
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 5
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 3
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 3
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims description 3
- 102100034980 ICOS ligand Human genes 0.000 claims description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 3
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 3
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 3
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 108010087819 Fc receptors Proteins 0.000 claims description 2
- 102000009109 Fc receptors Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 25
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 108091054438 MHC class II family Proteins 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 108010058607 HLA-B Antigens Proteins 0.000 description 2
- 108010052199 HLA-C Antigens Proteins 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 1
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 1
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 1
- 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 1
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013715P | 2014-06-18 | 2014-06-18 | |
| US62/013,715 | 2014-06-18 | ||
| PCT/US2015/035777 WO2015195531A2 (en) | 2014-06-18 | 2015-06-15 | Syntac polypeptides and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019192453A Division JP6652680B2 (ja) | 2014-06-18 | 2019-10-23 | ｓｙｎＴａｃポリペプチド及びその使用 |
| JP2020009921A Division JP6995151B2 (ja) | 2014-06-18 | 2020-01-24 | ｓｙｎＴａｃポリペプチド及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519491A JP2017519491A (ja) | 2017-07-20 |
| JP2017519491A5 true JP2017519491A5 (cg-RX-API-DMAC7.html) | 2018-07-26 |
| JP6652932B2 JP6652932B2 (ja) | 2020-02-26 |
Family
ID=54936224
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565693A Active JP6652932B2 (ja) | 2014-06-18 | 2015-06-15 | ｓｙｎＴａｃポリペプチド及びその使用 |
| JP2019192453A Active JP6652680B2 (ja) | 2014-06-18 | 2019-10-23 | ｓｙｎＴａｃポリペプチド及びその使用 |
| JP2020009921A Active JP6995151B2 (ja) | 2014-06-18 | 2020-01-24 | ｓｙｎＴａｃポリペプチド及びその使用 |
| JP2021202405A Active JP7331075B2 (ja) | 2014-06-18 | 2021-12-14 | ｓｙｎＴａｃポリペプチド及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019192453A Active JP6652680B2 (ja) | 2014-06-18 | 2019-10-23 | ｓｙｎＴａｃポリペプチド及びその使用 |
| JP2020009921A Active JP6995151B2 (ja) | 2014-06-18 | 2020-01-24 | ｓｙｎＴａｃポリペプチド及びその使用 |
| JP2021202405A Active JP7331075B2 (ja) | 2014-06-18 | 2021-12-14 | ｓｙｎＴａｃポリペプチド及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20170058015A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3483179B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6652932B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102252119B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN113248624B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2015277460B2 (cg-RX-API-DMAC7.html) |
| DK (2) | DK3157552T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2767259T3 (cg-RX-API-DMAC7.html) |
| HU (2) | HUE048076T2 (cg-RX-API-DMAC7.html) |
| IL (3) | IL248979B (cg-RX-API-DMAC7.html) |
| PL (2) | PL3480213T3 (cg-RX-API-DMAC7.html) |
| PT (2) | PT3480213T (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201609876TA (cg-RX-API-DMAC7.html) |
| TW (3) | TWI795740B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015195531A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3640375A3 (en) | 2012-12-11 | 2020-07-29 | Albert Einstein College of Medicine | Methods for high throughput receptor/ligand identification |
| JP2019516665A (ja) * | 2016-03-02 | 2019-06-20 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| JP7372036B2 (ja) * | 2016-03-03 | 2023-10-31 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| BR112018073606A2 (pt) * | 2016-05-18 | 2019-02-26 | Cue Biopharma, Inc. | polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos |
| WO2017201131A1 (en) * | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
| WO2018027252A1 (en) * | 2016-08-11 | 2018-02-15 | The Council Of The Queensland Institute Of Medical Research | Immune-modulating compounds |
| WO2018119114A1 (en) * | 2016-12-22 | 2018-06-28 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3596118B1 (en) * | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| US11407806B2 (en) * | 2017-04-06 | 2022-08-09 | Albert Einstein College Of Medicine | Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells |
| CN110869494B (zh) * | 2017-06-12 | 2025-02-18 | 西奈卫生系统公司 | 无需全身性免疫遏制的同种异体移植物耐受 |
| CN107266581B (zh) * | 2017-06-13 | 2021-07-09 | 四川大学 | 藏猪il-12重组质粒增强pcv2疫苗免疫佐剂的制备方法及应用 |
| US11708418B2 (en) * | 2017-08-10 | 2023-07-25 | Grifols Diagnostic Solutions Inc. | Compositions, methods and/or kits comprising a recombinant human CD38- extracellular domain |
| TW201925235A (zh) * | 2017-09-07 | 2019-07-01 | 美商信號生物製藥公司 | 具有化學結合位點之抗原呈現多肽及其使用方法 |
| JP2020534352A (ja) * | 2017-09-07 | 2020-11-26 | キュー バイオファーマ，インコーポレーテッド | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
| JP2021500855A (ja) * | 2017-09-07 | 2021-01-14 | キュー バイオファーマ， インコーポレイテッド | 抗原提示ポリペプチドおよびその使用方法 |
| EA202090471A1 (ru) * | 2017-09-07 | 2020-06-10 | Кью Биофарма, Инк. | Модулирующие т-клетки мультимерные полипептиды и способы их применения |
| WO2019106592A2 (en) * | 2017-11-30 | 2019-06-06 | Grifols Diagnostic Solutions Inc. | Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1 |
| EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
| EP3772927B1 (en) | 2018-03-24 | 2025-01-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| WO2020056152A1 (en) * | 2018-09-12 | 2020-03-19 | Chang Liu | Single chain constructs |
| CA3123102A1 (en) * | 2018-12-13 | 2020-06-18 | Sinai Health System | Immunomodulatory cells and uses thereof |
| EP3897690A4 (en) * | 2018-12-19 | 2022-09-28 | Cue Biopharma, Inc. | T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2020132138A1 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| TWI856047B (zh) * | 2018-12-19 | 2024-09-21 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| JP7691927B2 (ja) * | 2019-03-06 | 2025-06-12 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節抗原提示ポリペプチド及びその使用方法 |
| WO2020181062A1 (en) * | 2019-03-06 | 2020-09-10 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| AU2020282736B2 (en) * | 2019-05-29 | 2025-10-30 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| JP2022536581A (ja) * | 2019-06-19 | 2022-08-18 | キュー バイオファーマ， インコーポレイテッド | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| AU2020348373A1 (en) * | 2019-09-20 | 2022-02-24 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| AU2020370292A1 (en) * | 2019-10-23 | 2022-03-03 | Cue Biopharma, Inc. | T-cell modulatory chimeric molecules and methods of use thereof |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| US20230076204A1 (en) * | 2020-02-18 | 2023-03-09 | Institute For Systems Biology | Single chain trimer mhc class ii nucleic acids and proteins and methods of use |
| EP4106790A4 (en) * | 2020-02-21 | 2024-02-21 | 3T Biosciences, Inc. | YEAST DISPLAY LIBRARIES, RELATED COMPOSITIONS AND RELATED METHODS OF USE |
| US20230126784A1 (en) * | 2020-03-06 | 2023-04-27 | Albert Einstein College Of Medicine | A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity |
| JP2023525822A (ja) * | 2020-05-12 | 2023-06-19 | エルジー・ケム・リミテッド | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| AU2021272895A1 (en) | 2020-05-12 | 2022-09-22 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| WO2022056015A1 (en) * | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof |
| EP4211149A4 (en) | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
| CN112852744A (zh) * | 2021-01-27 | 2021-05-28 | 河南省华隆生物技术有限公司 | 一种nk滋养层细胞及其制备方法和应用 |
| CN112725284A (zh) * | 2021-01-27 | 2021-04-30 | 河南省华隆生物技术有限公司 | 一种nk滋养层细胞及其应用 |
| CN112779224A (zh) * | 2021-01-27 | 2021-05-11 | 河南省华隆生物技术有限公司 | 一种表达细胞因子组合物的nk滋养层细胞及其制备方法和应用 |
| CN112725273A (zh) * | 2021-01-27 | 2021-04-30 | 河南省华隆生物技术有限公司 | 一种nk细胞及其制备方法和应用 |
| WO2022197970A2 (en) * | 2021-03-19 | 2022-09-22 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| AU2022253266A1 (en) * | 2021-04-07 | 2023-11-23 | Repertoire Immune Medicines, Inc. | Peptide-mhc-immunoglobulin multimers and methods of use thereof |
| JP2024519500A (ja) * | 2021-05-07 | 2024-05-14 | インスティチュート フォー システムズ バイオロジー | 単鎖三量体ｍｈｃクラスｉ核酸およびタンパク質ならびに使用方法 |
| WO2023022965A2 (en) | 2021-08-16 | 2023-02-23 | Regeneron Pharmaceuticals, Inc. | Novel il27 receptor agonists and methods of use thereof |
| WO2023023641A2 (en) * | 2021-08-20 | 2023-02-23 | 3T Biosciences, Inc. | Peptide-hla-b*35 libraries, associated compositions, and associated methods of use |
| US20250059254A1 (en) * | 2022-01-03 | 2025-02-20 | Aarhus Universitet | Proteinaceous compound for generating specific cytotoxic t-cell effect |
| US20250271443A1 (en) * | 2022-04-21 | 2025-08-28 | Institute For Systems Biology | Soluble single-chain dimers from cleavable single chain trimers |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2024059740A1 (en) * | 2022-09-14 | 2024-03-21 | Synthego Corporation | Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof |
| EP4654982A1 (en) | 2023-01-27 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Modified rhabdovirus glycoproteins and uses thereof |
| WO2024182540A2 (en) | 2023-02-28 | 2024-09-06 | Regeneron Pharmaceuticals, Inc. | T cell activators and methods of use thereof |
| WO2025081106A2 (en) * | 2023-10-12 | 2025-04-17 | Vanderbilt University | Nanobody vaccine compositions |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| ES2197145T3 (es) | 1991-08-20 | 2004-01-01 | The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services | Transferencia de genes mediada por adenovirus al gastrointestinal. |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| HU223733B1 (hu) | 1993-10-25 | 2004-12-28 | Canji, Inc. | Rekombináns adenovírus vektor és eljárás alkalmazására |
| US5869270A (en) * | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| US6211342B1 (en) * | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
| US20050003431A1 (en) * | 1996-08-16 | 2005-01-06 | Wucherpfennig Kai W. | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| WO2002072631A2 (en) * | 2001-03-14 | 2002-09-19 | Dakocytomation Denmark A/S | Mhc molecule constructs and their usesfor diagnosis and therapy |
| DE102004014983A1 (de) * | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| AU2007223888A1 (en) | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Genetic packages and uses thereof |
| US8518697B2 (en) * | 2006-04-04 | 2013-08-27 | Washington University | Single chain trimers and uses therefor |
| EP2155782A2 (en) * | 2007-03-26 | 2010-02-24 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| EP2337795A2 (en) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| JP5843357B2 (ja) * | 2009-02-03 | 2016-01-13 | アムニクス オペレーティング インコーポレイテッド | 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物 |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| WO2014083004A1 (en) | 2012-11-30 | 2014-06-05 | Roche Glycart Ag | Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins |
| JP2020534352A (ja) * | 2017-09-07 | 2020-11-26 | キュー バイオファーマ，インコーポレーテッド | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
| EP3737689A4 (en) * | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
-
2015
- 2015-06-15 PT PT182128017T patent/PT3480213T/pt unknown
- 2015-06-15 JP JP2016565693A patent/JP6652932B2/ja active Active
- 2015-06-15 DK DK15809277.5T patent/DK3157552T3/da active
- 2015-06-15 EP EP18212805.8A patent/EP3483179B1/en active Active
- 2015-06-15 ES ES15809277T patent/ES2767259T3/es active Active
- 2015-06-15 EP EP15809277.5A patent/EP3157552B1/en active Active
- 2015-06-15 PL PL18212801T patent/PL3480213T3/pl unknown
- 2015-06-15 ES ES18212801T patent/ES2770330T3/es active Active
- 2015-06-15 CN CN202110210461.1A patent/CN113248624B/zh active Active
- 2015-06-15 US US15/306,678 patent/US20170058015A1/en not_active Abandoned
- 2015-06-15 CN CN202110210453.7A patent/CN113248623A/zh active Pending
- 2015-06-15 DK DK18212801.7T patent/DK3480213T3/da active
- 2015-06-15 PT PT158092775T patent/PT3157552T/pt unknown
- 2015-06-15 SG SG11201609876TA patent/SG11201609876TA/en unknown
- 2015-06-15 EP EP18212801.7A patent/EP3480213B1/en active Active
- 2015-06-15 CN CN201580027510.0A patent/CN106456733B/zh active Active
- 2015-06-15 HU HUE18212801A patent/HUE048076T2/hu unknown
- 2015-06-15 PL PL15809277T patent/PL3157552T3/pl unknown
- 2015-06-15 SG SG10202006338UA patent/SG10202006338UA/en unknown
- 2015-06-15 KR KR1020167034341A patent/KR102252119B1/ko active Active
- 2015-06-15 AU AU2015277460A patent/AU2015277460B2/en active Active
- 2015-06-15 WO PCT/US2015/035777 patent/WO2015195531A2/en not_active Ceased
- 2015-06-15 HU HUE15809277A patent/HUE047255T2/hu unknown
- 2015-06-17 TW TW110108178A patent/TWI795740B/zh active
- 2015-06-17 TW TW104119612A patent/TWI696633B/zh active
- 2015-06-17 TW TW108133859A patent/TWI722576B/zh active
-
2016
- 2016-11-15 IL IL248979A patent/IL248979B/en active IP Right Grant
-
2018
- 2018-06-06 US US16/001,153 patent/US20180282392A1/en not_active Abandoned
-
2019
- 2019-05-12 IL IL266570A patent/IL266570B/en active IP Right Grant
- 2019-05-16 AU AU2019203442A patent/AU2019203442B2/en active Active
- 2019-10-23 JP JP2019192453A patent/JP6652680B2/ja active Active
-
2020
- 2020-01-13 US US16/740,752 patent/US20200377569A1/en not_active Abandoned
- 2020-01-24 JP JP2020009921A patent/JP6995151B2/ja active Active
- 2020-06-11 IL IL275307A patent/IL275307B/en unknown
- 2020-08-25 US US17/001,847 patent/US20210238254A1/en not_active Abandoned
- 2020-09-09 US US17/015,282 patent/US20210047384A1/en active Pending
-
2021
- 2021-07-01 AU AU2021204594A patent/AU2021204594B2/en active Active
- 2021-12-14 JP JP2021202405A patent/JP7331075B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519491A5 (cg-RX-API-DMAC7.html) | ||
| JP2020511949A5 (cg-RX-API-DMAC7.html) | ||
| CN110325205B (zh) | T细胞调节性多聚体多肽及其使用方法 | |
| JP2020514375A5 (cg-RX-API-DMAC7.html) | ||
| CN111148756B (zh) | T细胞受体 | |
| JP2021500855A5 (cg-RX-API-DMAC7.html) | ||
| US20250074960A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| CN109311945A (zh) | T细胞调节性多聚体多肽及其使用方法 | |
| JP2019522466A5 (cg-RX-API-DMAC7.html) | ||
| WO2019051126A4 (en) | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof | |
| JP2016528244A (ja) | Ｔ細胞レセプター | |
| JP2014519830A5 (cg-RX-API-DMAC7.html) | ||
| JP2017507917A5 (cg-RX-API-DMAC7.html) | ||
| WO2020132368A4 (en) | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof | |
| US20240376177A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| US20230045794A1 (en) | Nk cell-directed chimeric proteins | |
| US20210284712A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| CN115867310A (zh) | 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物 | |
| CN107207622B (zh) | Hla-b27同二聚体用于癌症治疗的用途 | |
| JP2020521000A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020243315A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2021055594A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020257191A5 (cg-RX-API-DMAC7.html) | ||
| US20180355012A1 (en) | Soluble heterodimeric t cell receptor, and preparation method and use thereof | |
| US20230218731A1 (en) | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof |